The Role of PARP Inhibitors in Later Line Situations

Patient who's had prior PARP, are there situations where you would use it again? You would think maybe one situation would be somebody who gets it primarily, has it stopped and then recurs when they're not on it. So I mean, that is one thing. But what about somebody who's progressing on a PARP and can you justify switching to another one or continuing and adding something other than just not using it anymore? Well, let's take those three questions. If somebody's progressing on an existing PARP, absolutely not outside of clinical trial. In that scenario, it's always going to be in combination with another agent.